Aroldi, Francesca http://orcid.org/0000-0002-1202-0258
Middleton, Mark R.
Article History
Accepted: 1 March 2022
First Online: 31 March 2022
Declarations
:
: No external funding was used in the preparation of this manuscript.
: Francesca Aroldi received a travel grant to a congress from Nucana and is currently employed by AstraZeneca. Mark Middleton has received grants from Roche and AstraZeneca; grants and personal fees from GSK; personal fees and other from Novartis, BMS, and BioLineRx; grants, personal fees, and other from Immunocore; other from Pfizer and Regeneron; personal fees, non-financial support, and other from Merck/MSD; personal fees and non-financial support from Replimune; personal fees from Kineta and Silicon Therapeutics; and grants from GRAIL outside the submitted work
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: FA made a substantial contribution to the concept and design of the article, literature research, and drafted the article. MM made a substantial contribution to the interpretation of data for the article, and revised it critically for important intellectual content. FA and MM approved the version to be published.